GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Cyclically Adjusted Revenue per Share

TherapeuticsMD (TherapeuticsMD) Cyclically Adjusted Revenue per Share : $6.39 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

TherapeuticsMD's adjusted revenue per share for the three months ended in Dec. 2023 was $0.045. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.39 for the trailing ten years ended in Dec. 2023.

During the past 12 months, TherapeuticsMD's average Cyclically Adjusted Revenue Growth Rate was -3.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -32.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -45.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -44.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of TherapeuticsMD was -3.00% per year. The lowest was -60.10% per year. And the median was -35.15% per year.

As of today (2024-04-28), TherapeuticsMD's current stock price is $1.86. TherapeuticsMD's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $6.39. TherapeuticsMD's Cyclically Adjusted PS Ratio of today is 0.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TherapeuticsMD was 5.85. The lowest was 0.06. And the median was 1.02.


TherapeuticsMD Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for TherapeuticsMD's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Cyclically Adjusted Revenue per Share Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.64 21.02 5.85 6.61 6.39

TherapeuticsMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.61 6.63 6.60 6.54 6.39

Competitive Comparison of TherapeuticsMD's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Cyclically Adjusted PS Ratio falls into.



TherapeuticsMD Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TherapeuticsMD's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.045/129.4194*129.4194
=0.045

Current CPI (Dec. 2023) = 129.4194.

TherapeuticsMD Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.976 99.695 1.267
201406 1.289 100.560 1.659
201409 1.375 100.428 1.772
201412 1.364 99.070 1.782
201503 1.369 99.621 1.778
201506 1.403 100.684 1.803
201509 1.464 100.392 1.887
201512 1.582 99.792 2.052
201603 1.265 100.470 1.629
201606 1.121 101.688 1.427
201609 1.409 101.861 1.790
201612 1.141 101.863 1.450
201703 1.007 102.862 1.267
201706 1.045 103.349 1.309
201709 1.062 104.136 1.320
201712 0.971 104.011 1.208
201803 0.871 105.290 1.071
201806 0.868 106.317 1.057
201809 0.762 106.507 0.926
201812 1.066 105.998 1.302
201903 0.819 107.251 0.988
201906 1.260 108.070 1.509
201909 4.916 108.329 5.873
201912 3.036 108.420 3.624
202003 2.257 108.902 2.682
202006 1.968 108.767 2.342
202009 3.548 109.815 4.181
202012 3.938 109.897 4.638
202103 2.860 111.754 3.312
202106 2.919 114.631 3.296
202109 3.009 115.734 3.365
202112 -7.681 117.630 -8.451
202203 0.081 121.301 0.086
202206 0.040 125.017 0.041
202209 0.038 125.227 0.039
202212 6.329 125.222 6.541
202303 0.043 127.348 0.044
202306 0.043 128.729 0.043
202309 -0.005 129.860 -0.005
202312 0.045 129.419 0.045

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


TherapeuticsMD  (NAS:TXMD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TherapeuticsMD's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.86/6.39
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TherapeuticsMD was 5.85. The lowest was 0.06. And the median was 1.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


TherapeuticsMD Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (TherapeuticsMD) Business Description

Industry
Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Executives
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro director
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354

TherapeuticsMD (TherapeuticsMD) Headlines

From GuruFocus

SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.

By PRNewswire PRNewswire 06-20-2022